Evidence map›Paper›PMID 41049273›Full record

ArticleAdvanced therapeutics2023

Enzyme-Based Synthetic Protein Nanoparticles as Colloidal Antioxidants.

Ava Mauser, Daniel F Quevedo, Boya Zhang, Yazmin Hernandez, Anthony Berardi, William Brown, Sophia Lee, Rikako Miki, Jeffery Raymond, Joerg Lahann and 1 more

Abstract read
In one paragraph

Article in Advanced therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Surface-Capped Protein Nanoparticles for Nonviral Gene Delivery.Advanced materials (Deerfield Beach, Fla.) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ava MauserDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Daniel F QuevedoDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Boya ZhangBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Yazmin HernandezDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Anthony BerardiBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
William BrownBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Sophia LeeBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Rikako MikiDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Jeffery RaymondBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Joerg LahannDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Colin F GreinederBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.

Funding

Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics (Supplement)R01NS124167 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro, JOERG LAHANN · 2022 to 2026
$2.6M
ICAM-1 targeted thrombomodulin: an experimental therapeutic for the Acute Respiratory Distress SyndromeK08HL130430 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI GREINEDER, COLIN FRED · 2016 to 2020
$665k
NHLBI NIH HHS K08 HL130430NINDS NIH HHS R01 NS124167
6 · The paper itself

Abstract

Protein-based drug delivery systems have gained popularity due to their biocompatibility, straightforward surface modification, and potential for intrinsic therapeutic activity. Among therapeutic proteins, enzymes are particularly attractive because of their specificity, efficient reaction rates, regeneration after substrate turnover, and proven track record in the treatment of diseases ranging from cancer to inherited metabolic and lysosomal storage disorders. Herein, previous work on electrohydrodynamic jetting is expanded upon by developing a novel class of protein nanoparticles that features therapeutic enzymes. In particular, nanoparticles incorporating the antioxidant enzyme, catalase, at weight fractions as high as 50% are reported. Catalase-based synthetic protein nanoparticles (CAT-SPNPs) demonstrate sustained antioxidative activity, retain significantly enhanced enzymatic activity compared to its solute form, and overall demonstrate good structural stability. Moreover, surface functionalization of CAT-SPNPs with targeting antibodies results in ≈12.5-fold increase in uptake over unmodified control particles. Importantly, CAT-SPNPs exert protection from oxidative stress, as indicated by significant increase in viability and reduction in LDH release compared to equivalent amounts of free catalase. Taken together, the work establishes targeted enzyme-based SPNPs as a platform for enhancing the drug-like properties of therapeutic enzymes.

Indexed as

catalaseenzyme therapiesnanomedicineprotein nanoparticlestargeting

Identifiers

PMID41049273
PMCPMC12492989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.